Loading clinical trials...
Loading clinical trials...
This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis
NCT06846281 · Relapsing Multiple Sclerosis
NCT06847724 · Relapsing Multiple Sclerosis
NCT05344469 · Relapsing Multiple Sclerosis
NCT07426991 · Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, and more
Novartis Investigative Site
Box Hill
Novartis Investigative Site
Heidelberg
Novartis Investigative Site
Kogarah
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions